Maruho Pharmaceutical China: The company has completed the name change of its Chinese entity.

On December 1st, Maruho Pharmaceutical China announced that on July 31, 2025, the company's former parent company, Sumitomo Pharmaceuticals Co., Ltd. of Japan, had successfully completed the equity transfer transaction with Maruho Global Pharmaceuticals Co., Ltd. From now on, the company and all its affiliated companies in China officially joined the Maruho Group of Japan. In order to meet the strategic development and operational management needs of the company, and with the approval of the relevant government departments, the company has completed the name change of its main entity in China. The company's abbreviation has been changed from "Sumitomo Pharmaceutical Group China" to "Maruho Pharmaceutical China." The company name change is only a change in the enterprise registration matters, which does not affect the continuation of the company's legal status, rights, obligations under the original contracts, and agreements, the agreements signed with various partners that have not yet been fulfilled will remain valid, and business cooperation with partners will continue to be performed as originally agreed.